10x Genomics, Inc. Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount
10x Genomics, Inc. (TXG) reported Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount of $36.38 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-13.
Financial Statements › Notes › Income Taxes
us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount · last filed 2026-02-13
- 10x Genomics, Inc. effective income tax rate reconciliation, tax expense (benefit), share-based payment arrangement, amount for fiscal 2024 was $36.38M, a 54.27% decline from fiscal 2023.
- 10x Genomics, Inc. effective income tax rate reconciliation, tax expense (benefit), share-based payment arrangement, amount for fiscal 2023 was $79.55M, a 58.86% increase from fiscal 2022.
- 10x Genomics, Inc. effective income tax rate reconciliation, tax expense (benefit), share-based payment arrangement, amount for fiscal 2022 was $50.08M, a 60.38% decline from fiscal 2021.
- 10x Genomics, Inc. effective income tax rate reconciliation, tax expense (benefit), share-based payment arrangement, amount for fiscal 2021 was $126.39M, a 27.62% increase from fiscal 2020.
| Period end | Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount 12 month |
|---|---|
| 2024-12-31 | $36.38M 10-K · filed 2026-02-13 |
| 2023-12-31 | $79.55M 10-K · filed 2026-02-13 |
| 2022-12-31 | $50.08M 10-K · filed 2025-02-13 |
| 2021-12-31 | $126.39M 10-K · filed 2024-02-15 |
| 2020-12-31 | $99.03M 10-K · filed 2023-02-16 |
| 2019-12-31 | $10.78M 10-K · filed 2022-02-18 |
| 2018-12-31 | $19.13M 10-K · filed 2020-02-27 |